GNLX vs. CNTB, MIST, MCRB, RVPH, ALLK, ORMP, BRNS, DMAC, ANIX, and RNAC
Should you be buying Genelux stock or one of its competitors? The main competitors of Genelux include Connect Biopharma (CNTB), Milestone Pharmaceuticals (MIST), Seres Therapeutics (MCRB), Reviva Pharmaceuticals (RVPH), Allakos (ALLK), Oramed Pharmaceuticals (ORMP), Barinthus Biotherapeutics (BRNS), DiaMedica Therapeutics (DMAC), Anixa Biosciences (ANIX), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical preparations" industry.
Connect Biopharma (NASDAQ:CNTB) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, community ranking, profitability, earnings, analyst recommendations, valuation and risk.
In the previous week, Genelux had 3 more articles in the media than Connect Biopharma. MarketBeat recorded 7 mentions for Genelux and 4 mentions for Connect Biopharma. Genelux's average media sentiment score of 0.96 beat Connect Biopharma's score of 0.48 indicating that Connect Biopharma is being referred to more favorably in the media.
Connect Biopharma presently has a consensus target price of $6.50, indicating a potential upside of 392.42%. Genelux has a consensus target price of $34.00, indicating a potential upside of 900.00%. Given Connect Biopharma's higher possible upside, analysts clearly believe Genelux is more favorable than Connect Biopharma.
Connect Biopharma received 9 more outperform votes than Genelux when rated by MarketBeat users. However, 100.00% of users gave Genelux an outperform vote while only 69.57% of users gave Connect Biopharma an outperform vote.
Genelux has higher revenue and earnings than Connect Biopharma.
Genelux's return on equity of 0.00% beat Connect Biopharma's return on equity.
Connect Biopharma has a beta of -0.61, meaning that its share price is 161% less volatile than the S&P 500. Comparatively, Genelux has a beta of -3.21, meaning that its share price is 421% less volatile than the S&P 500.
58.7% of Connect Biopharma shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by company insiders. Comparatively, 11.7% of Genelux shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Connect Biopharma beats Genelux on 7 of the 13 factors compared between the two stocks.
Get Genelux News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
